Developing a new HIV vaccine to enhance immune responses
Official title: Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo
Funded at Wistar Institute · NIH-11011258 · Data updated 2026-11-12
This study is looking for people to help test new HIV vaccines that aim to boost your immune system's ability to fight the virus by using special ingredients that help your body recognize and respond to it better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 8, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $924,582 |
| NIH project number | 5U19AI166916-03 |
| Project ID | NIH-11011258 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals at risk for HIV or those living with HIV who are seeking new treatment options.
✕Less likely to help
Patients who are not at risk for HIV or those who have already achieved viral suppression with existing therapies may not benefit from this research.
What this research studies
This research focuses on creating innovative vaccine candidates for HIV-1 that can stimulate strong immune responses, including the production of neutralizing antibodies and T cell responses. The approach involves using DNA-launched immunogens that self-assemble in the body to present the right targets for the immune system while avoiding those that could lead to ineffective responses. By combining these immunogens with molecular adjuvants, the research aims to enhance the body's ability to fight HIV effectively. Patients may have the opportunity to participate in clinical trials that test these new vaccine candidates.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that significantly improves immune protection against the virus.
How similar studies have gone: Previous research has shown promise in developing similar vaccine strategies, indicating potential for success in this novel approach.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Weiner, David B. — Wistar Institute
- Study coordinator: Weiner, David B.
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.